CAS: 105239-91-6; Cefclidin

该化合物是一种属于甲状腺-甲状腺素类的合成抗生素,其特点是乙型乳腺结构,主要用于抗菌特性,对一系列抗菌性细菌和丙型阴性细菌有效;Cefclidin通过抑制细菌细胞壁合成,导致细胞分解和死亡,进行工作,通常通过注射施用,并因其稳定性而闻名于某些乙型乳腺,这些乙型乳腺是某些细菌为抵抗抗生素行动而生成的酶;其药用动力学学包括人体组织内良好的吸收和分布,尽管其新陈代谢和排出物的具体细节可能有所不同;常见副作用可能包括胃肠紊乱,过敏反应和对肾功能的潜在影响;与其他抗生素一样,必须明智地使用丙基里丁来防止抗生素抗体的生长;

结构式图片

MSDS等安全信息

    合成工艺路线路线简述

      专利信息


      专利号:US-9066864-B2
      优先权日:2011-01-12
      标 题:Use of liquid medium exchange by cross flow filtration in the preparation of drug suspensions
      发明人:NIEDERMANN HANS PETER; BOTHE HEIKO
      权利人:NIEDERMANN HANS PETER; BOTHE HEIKO; INTERVET INC
      摘要:Disclosed is a method of making particles of a drug wherein use is made of diafiltration. The diafiltration can be with anti-solvent, in which case a precipitate is obtained of particles as such. The diafiltration can also be with a pharmaceutically acceptable suspension medium. In that case several process steps of isolating, drying, transporting of particles can be avoided, because the suspension resulting from the synthesis of the particles is directly turned into a final drug product formulation.

      专利号:US-2009111737-A1
      优先权日:1999-05-24
      标题:Novel antibacterial agents
      发明人:CHRISTENSEN BURTON G; MORAN EDMUND J; GRIFFIN JOHN H; JUDICE J KEVIN; MU YONGQI; PACE JOHN L; MAMMEN MATHAI; AGGEN JAMES
      权利人:CHRISTENSEN BURTON G; MORAN EDMUND J; GRIFFIN JOHN H; JUDICE J KEVIN; MU YONGQI; PACE JOHN L; MAMMEN MATHAI; AGGEN JAMES
      摘要:This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands in their monovalent (i.e., unlinked) state have the ability to bind to a an enzyme involved in cell wall biosynthesis and metabolism, a precursor used in the synthesis of the bacterial cell wall and/or the bacterial cell surface thereby interfere with the synthesis and/or metabolism of the cell wall. In particular the multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligands hasn a ligand domain capable of binding to penicillin binding proteins, a transpeptidase enzyme, a substrate of a transpeptidase enzyme, a beta-lactamase enzyme, pencillinase enzyme, cephalosporinase enzyme, a transglycoslase enzyme, or a transglycosylase enzyme substrate; Preferably, the ligands are selected from the beta lactam or glycopeptide class of antibacterial agents.

      专利号:US-2011015119-A1
      优先权日:2009-06-24
      标题:Novel semi-synthetic glycopeptides as antibacterial agents
      发明人:CHU DANIEL; YE TAO; WANG BING
      权利人:LEAD THERAPEUTICS INC
      摘要:Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopeptides described herein are made by chemical modification of a glycopeptide (Compound A, Compound B, Compound H or Compound C) or monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety on these scaffolds with certain acyl groups; and conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides. Key reaction is the treatment of properly protected intermediate compound with isocyanate. Also provided are methods for the synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections.

      专利号:NZ-505979-A
      优先权日:1998-06-08
      标 题 :Multibinding antibacterial agents comprising 2 antibiotic or aglycone ligands, connected by a linker, capable of affecting cell wall synthesis or metabolism

      供应商参考报价(招募中)

      品牌试剂参考报价(招募中)

      📌 第三方产品分析报告

      ✅ COA系统入驻 | 共享模式

      主要参考文献


      1: Watanabe NA, Katsu K. Cefclidin (E1040), a novel cephalosporin: lack of selection of beta-lactamase overproducing mutants in an in vitro pharmacokinetic model system. J Antibiot (Tokyo). 1992 Aug;45(8):1335-45. doi: 10.7164/antibiotics.45.1335. 30(5):633-41. doi: 10.1093/jac/30.5.633. 30(4):475-87. doi: 10.1093/jac/30.4.475. 38(4):507-10. Japanese. 45(9):1526-32. doi: 10.7164/antibiotics.45.1526. 40(8):689-94. 46(1):18-30. 19(9):534-6. doi: 10.1111/j.1346-8138.1992.tb03724.x. 45(5):512-22. Japanese. 36(12):2595-601. doi: 10.1128/aac.36.12.2595.

      合成参考文献


      参考文献:10.1093/jac/30.5.633
      摘要:Watanabe N, Hiruma R, Katsu K. Comparative in-vitro activities of newer cephalosporins cefclidin, cefepime, and cefpirome against ceftazidime- or imipenem-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 1992 Nov;30(5):633–41. doi: 10.1093/jac/30.5.633.
      参考文献:10.1128/aac.36.7.1580
      摘要:Satoh M, Munakata K, Takeuchi H, Yoshida O. Evaluation of the Usefulness of a Novel Injectable Cephalosporin, E1040, and Ceftazidime for Management of Complicated Urinary Tract Infections Caused by Pseudomonas aeruginosa and Proteus mirabilis by Using the Rat Urolithiasis Model. Antimicrob Agents Chemother. 1992 Jul;36(7):1580–3. doi: 10.1128/aac.36.7.1580.
      摘要:Tatsumi N, Im T, Furukawa Y, Sannomiya Y, Inoue K, Kageyama T, Ohyabu H, Akasaka K, Nasu K, Yonezawa T. [Therapeutic effects of cefclidin against severe infections in patients with hematopoietic disorders. Hanshin Infection Study Group]. Jpn J Antibiot. 1992 May;45(5):512–22.
      摘要:Watanabe N, Asakawa N, Toyosawa T, Hiruma R, Hata K, Ueno J, Katsu K, Yoshida Y. [Effect of cefclidin and E1077, new cephalosporins, on the alcohol-metabolizing system in rats]. Jpn J Antibiot. 1992 Apr;45(4):364–70.
      参考文献:10.2165/00003495-199447030-00007
      摘要:Barradell LB, Bryson HM. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1994 Mar;47(3):471–505. doi: 10.2165/00003495-199447030-00007.
      📝 需求与反馈
      尽可能描述清楚需求与问题信息
      ×

      通知